US Stock Market Movement: Biohaven Surges on October 22nd as FDA Accepts Resubmission and SCA Drug Application

Biohaven October 22nd Surge Interpretation

Keywords: FDA resubmission acceptance, SCA medication

On October 22, 2026, the FDA accepted Biohaven's resubmitted New Drug Application for Vyglxiatroriluzole for the treatment of spinocerebellar ataxia (SCA). The resubmission includes new positive supportive analyses, and the FDA considers it a complete response to the action letter dated November 4, 2025, setting a review target date for the first quarter of 2027. The FDA also plans to convene a Peripheral and Central Nervous System Drugs Advisory Committee meeting to gather external opinions, with the specific date to be announced.

(Disclaimer: This content is compiled and summarized by AI technology from publicly available information and is for reference only. It does not constitute investment advice.)